DiaSorin (OTCMKTS:DSRLF) Shares Gap Down – Should You Sell?

DiaSorin S.p.A. (OTCMKTS:DSRLF)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $70.76, but opened at $67.00. DiaSorin shares last traded at $67.00, with a volume of 100 shares changing hands.

Analyst Upgrades and Downgrades

DSRLF has been the subject of a number of recent research reports. BNP Paribas Exane upgraded DiaSorin to a “neutral” rating in a research note on Wednesday, January 28th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of DiaSorin in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, DiaSorin has an average rating of “Moderate Buy”.

DiaSorin Stock Down 5.3%

The firm’s 50 day simple moving average is $80.48 and its 200 day simple moving average is $81.62.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.